复发性卵巢子宫内膜异位症患者发生深部DIE的危险因素

doi:10.3760/cma.j.cn441417-20241112-16008

摘要/Abstract

摘要：

目的　探讨复发性卵巢子宫内膜异位症（EMT）患者发生深部浸润型子宫内膜异位症（DIE）的危险因素。方法　采用回顾性分析，选取2020年8月至2022年11月在西安国际医学中心医院进行治疗的120例复发性卵巢EMT患者，根据患者病理结果分为DIE组（35例）、非DIE组（85例）。DIE组年龄（34.25±4.17）岁，病程（2.36±0.25）年；非DIE组年龄（33.69±4.55）岁，病程（2.31±0.27）年。比较两组患者的临床资料。采用t、χ²检验进行统计比较，logistic回归分析影响复发性卵巢EMT患者发生DIE的危险因素。结果　两组痛经程度与血清糖类抗原（CA）125、CA199、白细胞介素（IL）-8、肿瘤坏死因子（TNF-α）、IL-6水平比较，差异均有统计学意义（均P<0.05）。Logistic回归分析发现，重度痛经与高血清CA125、CA199、IL-8、TNF-α、IL-6水平是影响复发性卵巢EMT发生DIE的危险因素（均P<0.05）。结论　临床需加强对重度痛经及高血清CA125、CA199、IL-8、TNF-α、IL-6水平复发性卵巢EMT患者的检测，并及时采取干预措施，降低DIE发生风险。

关键词:

卵巢子宫内膜异位症, 复发性, 深部浸润型子宫内膜异位症, 危险因素

Abstract:

Objective　To explore the risk factors of deeply infiltrating endometriosis (DIE) in patients with recurrent ovarian endometriosis (EMT). Methods　A retrospective analysis was conducted on 120 patients with recurrent ovarian EMT treated in Xi'an International Medical Center Hospital from August 2020 to November 2022. The patients were divided into a DIE group (35 cases) and a non-DIE group (85 cases) according to their pathological results. The DIE group were (34.25±4.17) years old, with a disease course of (2.36±0.25) years. The non-DIE group were (33.69±4.55) years old, with a disease course of (2.31±0.27) years. The clinical data were compared between the two groups. Logistic regression was used to analyze the risk factors of DIE in the patients. Results　There were statistical differences in the serum levels of carbohydrate antigen 125 (CA125), serum carbohydrate antigen 199 (CA199), interleukin-8 (IL-8), tumor necrosis factor (TNF-α), and interleukin-6 (IL-6) between the two groups (all P<0.05). The logistic regression analysis showed that severe dysmenorrhea and high serum levels of CA125, CA199, IL-8, TNF-α, and IL-6 were risk factors for recurrent EMT to develop DIE (all P<0.05). Conclusion　It needs to clinically strengthen the detection of severe dysmenorrhea and high serum levels of CA125, CA199, IL-8, TNF-α, and IL-6 in patients with recurrent ovarian EMT, and take timely intervention measures to reduce the risk of DIE.

Key words:

Endometriosis of the ovary, Recurrence, Deeply infiltrating endometriosis, Risk factors

肖莉莎胡娜张奥雪陆美荣.

复发性卵巢子宫内膜异位症患者发生深部DIE的危险因素 [J]. 国际医药卫生导报, 2025, 31(16): 2679-2682.

Xiao Lisha, Hu Na, Zhang Aoxue, Lu Meirong.

Risk factors of deeply DIE in patients with recurrent ovarian endometriosis [J]. International Medicine and Health Guidance News, 2025, 31(16): 2679-2682.

参考文献

[1] 郑玉梅, 彭超, 陆叶, 等. 深部浸润型子宫内膜异位症在盆腔子宫内膜异位症中的发生率及其临床病理特征分析[J]. 中华妇产科杂志, 2020, 55(6): 384-389. DOI: 10.3760/cma.j.cn112141-20191202-00654.
[2] 董望舒. 深部浸润型子宫内膜异位症患者相关肠道功能紊乱的康复指导[J]. 中国妇幼保健, 2020, 35(4): 627-630. DOI: 10.19829/j.zgfybj.issn.1001-4411.2020.04.014.
[3] 孙丽. 促性腺激素释放激素激动剂联合地屈孕酮对深部浸润型子宫内膜异位症患者的临床疗效[J]. 中国临床药学杂志, 2019, 28(5): 337-341. DOI: 10.19577/j.1007-4406.2019.05.004.
[4] 唐文娟. 深部浸润型子宫内膜异位症的临床病理特征分析[J]. 检验医学与临床, 2021, 18(8): 1107-1109. DOI: 10.3969/j.issn.1672-9455.2021.08.021.
[5] 彭超, 周应芳. 复发性卵巢子宫内膜异位症的管理[J]. 中国实用妇科与产科杂志, 2022, 38(5): 491-495. DOI: 10.19538/j.fk2022050104.
[6] 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南[J]. 中华妇产科杂志, 2015, 50(3): 161-169. DOI: 10.3760/cma.j.issn.0529-567x.2015.03.001.
[7] 山东省疼痛医学会妇产科专业委员会, 山东省医师协会女性盆底功能障碍防治医师分会. 深部浸润型子宫内膜异位症多学科诊治的专家共识(2022年版)[J]. 北京医学, 2022, 44(12): 1113-1119. DOI: 10.15932/j.0253-9713.2022.12.040.
[8] 中国医师协会妇产科医师分会子宫内膜异位症专业委员会, 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症长期管理中国专家共识[J]. 中华妇产科杂志, 2018, 53(12): 836-841. DOI: 10.3760/cma.j.issn.0529-567x.2018.12.007.
[9] 孙馥箐, 段华, 汪沙. 深部浸润型子宫内膜异位症对妊娠及分娩结局影响的研究进展[J]. 中国计划生育和妇产科, 2021, 13(5): 20-24. DOI: 10.3969/j.issn.1674-4020.2021.05.06.
[10] Del Forno S, Arena A, Pellizzone V, et al. Assessment of levator hiatal area using 3D/4D transperineal ultrasound in women with deep infiltrating endometriosis and superficial dyspareunia treated with pelvic floor muscle physiotherapy: randomized controlled trial[J]. Ultrasound Obstet Gynecol, 2021, 57(5): 726-732. DOI: 10.1002/uog.23590.
[11] Quintairos RDA, Brito LGO, Farah D, et al. Conservative versus radical surgery for women with deep infiltrating endometriosis: systematic review and meta-analysis of bowel function[J]. J Minim Invasive Gynecol, 2022, 29(11): 1231-1240. DOI: 10.1016/j.jmig.2022.09.551.
[12] 段婧, 赵曰明, 郭世山. 深部浸润型子宫内膜异位症临床特征及其血清炎性因子表达[J]. 中国计划生育学杂志, 2022, 30(5): 1110-1114. DOI: 10.3969/j.issn.1004-8189.2022.05.031.
[13] 赵婷玉, 杨新春, 鲍美如, 等. 子宫内膜异位症痛经的临床特点及相关因素分析[J]. 世界中医药, 2023, 18(8): 1192-1197. DOI: 10.3969/j.issn.1673-7202.2023.08.023.
[14] Acimovic M, Vidakovic S, Milic N, et al. Survivin and VEGF as novel biomarkers in diagnosis of endometriosis[J]. J Med Biochem, 2016, 35(1): 63-68. DOI: 10.1515/jomb-2015-0005.
[15] Oliveira MAP, Raymundo TS, Soares LC, et al. How to use CA-125 more effectively in the diagnosis of deep endometriosis[J]. Biomed Res Int, 2017, 2017: 9857196. DOI: 10.1155/2017/9857196.
[16] 汪沙. 深部浸润型子宫内膜异位症相关不孕治疗的研究进展[J]. 中国微创外科杂志, 2023, 23(7): 528-532. DOI: 10.3969/j.issn.1009-6604.2023.07.009.
[17] Sarbazi F, Akbari E, Karimi A, et al. The clinical outcome of laparoscopic surgery for endometriosis on pain, ovarian reserve, and cancer antigen 125 (CA-125): a cohort study[J]. Int J Fertil Steril, 2021, 15(4): 275-279. DOI: 10.22074/IJFS.2021.137035.1018.
[18] 吴瑜诗, 李晓燕, 戴毅, 等. 卵巢子宫内膜异位囊肿合并DIE患者的临床特征和腹腔镜手术后的远期预后[J]. 中华妇产科杂志, 2021, 56(12): 842-848. DOI: 10.3760/cma.j.cn112141-20211009-00576.
[19] Fahrmann JF, Schmidt CM, Mao XY, et al. Lead-Time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection[J]. Gastroenterology, 2021, 160(4): 1373-1383.e6. DOI: 10.1053/j.gastro.2020.11.052.
[20] 宋宏, 尚小巧, 田宏. 血清IL-8、TIMP-1、单核细胞趋化因子-1在子宫内膜异位症中的表达及与疾病分期的关系[J]. 实验与检验医学, 2022, 40(3): 298-301, 305. DOI: 10.3969/j.issn.1674-1129.2022.03.013.
[21] Perricos A, Husslein H, Kuessel L, et al. Does the use of the "proseek® multiplex inflammation I panel" demonstrate a difference in local and systemic immune responses in endometriosis patients with or without deep-infiltrating lesions?[J]. Int J Mol Sci, 2023, 24(5): 5022. DOI: 10.3390/ijms24055022.
[22] Nishimoto-Kakiuchi A, Sato I, Nakano K, et al. A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosis[J]. Sci Transl Med, 2023, 15(684): eabq5858. DOI: 10.1126/scitranslmed.abq5858.
[23] 赵蓉. 深部浸润型子宫内膜异位症的危险因素分析[J]. 中国妇幼保健, 2016, 31(21): 4364-4366. DOI: 10.7620/zgfybj.j.issn.1001-4411.2016.21.14.
[24] 师瑶, 段君熠, 赵烨. 卵巢子宫内膜异位囊肿术后复发危险因素及药物治疗研究进展[J]. 实用药物与临床, 2022, 25(9): 843-847. DOI: 10.14053/j.cnki.ppcr.202209017.
[25] Nati ID, Malutan A, Ciortea R, et al. Exploring the influence of IL-8, IL-10, patient-reported pain, and physical activity on endometriosis severity[J]. Diagnostics, 2024, 14(16): 1822. DOI: 10.3390/diagnostics14161822.